At an inflexion point

Company

14 Oct 2024 | 5 Min Read

Tushar Manudhane upgrades IPCA Laboratories to Buy with a target price of INR 1,950.

IPCA's stock info: market cap of INR 419.8 billion, 52-week range of INR 933 to 1659.

Financial snapshot for FY25E: sales of INR 88.9 billion, EBITDA of INR 17.2 billion, adjusted PAT of INR 8.5 billion.

IPCA expected to sustain industry-beating growth in domestic formulation market and generics exports.

Efforts to revive US business, improve MR productivity, and market share gain.

Export formulation business expected to grow at a CAGR of 28% over FY24-27.